Pharmaceutical Resource Technology, Inc.

CIK:0001865759|SEC Filings

Condensed Consolidated Statement of Operations (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Condensed Consolidated Statement of Operations (UNAUDITED)
Revenue (Related Party)	$ 2,902,598	$ 3,030,475	$ 5,635,715	$ 5,432,172
Cost of revenue (Related Party)	(1,351,309)	(1,008,462)	(3,126,990)	(2,330,357)
Gross profit / loss	1,551,289	2,022,013	2,508,725	3,101,815
Operating Expenses
General and administrative expenses (Related Party)	(1,277,590)	(1,079,222)	(2,830,902)	(2,221,571)
Profit/Loss Before Income Tax	273,699	942,791	(322,177)	880,244
Income tax expenses	0	0	0	0
Net Profit/Loss	$ 273,699	$ 942,791	$ (322,177)	$ 880,244
Loss per share:
Basic and diluted net gain/loss per common share	$ (0.00)	$ 0.00	$ (0.00)	$ 0.00
Basic and diluted weighted average number of shares outstanding	2,854,462,696	2,790,917,545	2,854,462,696	2,790,917,545

Condensed Consolidated Cash Flow Statement (UNAUDITED) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net Profit/loss	$ (322,177)	$ 880,244
Depreciation of property, plant and equipment	684,006	766,531
Depreciation of right of use asset	78,197	78,197
Amortization	807,286	807,286
Changes in operating assets and liabilities
Inventories (Related Party)	(13,262)	(747,500)
Accrued expenses (Related Party)	31,023	160,800
Account Receivable	(51,941)	44,520
Lease liability	(122,547)	(127,540)
Net generated from operating activities	1,090,585	1,862,538
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment (Related Party)	0	0
Additions to right of use asset	0	0
Purchase of intangible assets	(364,200)	0
Net cash used in investing activities	(364,200)	0
CASH FLOWS FROM FINANCING ACTIVITY
Proceeds from the issuance of common stock / Loan	0	1,003,673
Net cash generated from financing activity	0	1,003,673
CASH FLOWS FROM REPAYMENT ACTIVITY
Repayment of debt owed to Directors (Related Party)	0	(2,500,000)
Net cash used in repayment activity	0	(2,500,000)
NET INCREASE IN CASH AND CASH EQUIVALENTS	726,385	366,211
Cash and cash equivalents, beginning of period	2,855,160	2,339,189
Cash and cash equivalents, end of period	$ 3,581,545	$ 2,705,400

Condensed Consolidated Balance Sheet - USD ($)	Jun. 30, 2026	Dec. 31, 2025
CURRENT ASSETS
Cash and Cash Equivalent	$ 3,581,545	$ 2,855,160
Account Receivable (Related Party)	1,053,054	1,001,113
Inventories (Related Party)	599,891	586,629
TOTAL CURRENT ASSETS	5,234,490	4,442,902
Property, plant and equipment	3,321,447	4,001,253
Right of use asset	1,937,107	2,015,304
Intangible assets	18,599,444	19,046,731
TOTAL ASSETS	29,092,488	29,506,190
CURRENT LIABILITIES
Accrued expenses / payable (Related Party)	58,523	27,500
Lease liability - current (Related Party)	122,548	125,019
TOTAL CURRENT LIABILITIES	181,071	152,519
Lease liability - non-current (Related Party)	411,407	531,484
TOTAL LIABILITIES	592,478	684,003
STOCKHOLDERS' EQUITY
Common stock $0.01 par value, 3,000,000,000 shares, authorized as at June 30, 2026 2,854,462,696 shares issued and outstanding as at June 30, 2026	28,544,627	28,544,627
Additional paid-in capital	290,643	290,643
Accumulated deficits	(335,260)	(13,083)
TOTAL STOCKHOLDERS' EQUITY	28,500,010	28,822,187
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 29,092,488	$ 29,506,190